Q-omics provides the consensus-scored PRPSAP2 profile across patient tissues and cancer cell-line models. PRPSAP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PRPSAP2 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, PRPSAP2 RNA expression shows 20,067 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, KICH, and ACC as cancer lineages where PRPSAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRPSAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRPSAP2 survival associations across molecular data types. PRPSAP2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRPSAP2 RNA expression–survival associations across cancer types. High PRPSAP2 expression shows unfavorable associations in ACC, but favorable associations in UCS, KIRC, PAAD, BRCA and LGG. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for PRPSAP2 RNA expression.
This table summarizes PRPSAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRPSAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRPSAP2 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LIHC, STAD and CHOL. The KICH box plot shows higher PRPSAP2 RNA expression in normal versus tumor tissue (log2 FC = −1.652, t-test p < 0.001).
This table shows molecular features associated with PRPSAP2 in patient tissues and cancer cell lines. In patient samples, PRPSAP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRPSAP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
